Peptides researched for recovery and tissue repair
Peptides studied for wound healing, connective-tissue repair and post-exertion adaptation.
Overview
Tissue-repair biology is one of the more practically motivated areas of peptide research, with substantial published work on wound healing, tendon and ligament repair, and post-exertion adaptation. The compounds that dominate this literature — GHK-Cu, BPC-157 and Thymosin Beta-4 (TB-500) — operate through fundamentally different mechanisms but converge on overlapping repair outcomes.
This page surveys peptides with published recovery-related evidence. The longevity-research framing here is that ageing reduces the rate and completeness of tissue repair across organ systems — connective tissue, vasculature, gastrointestinal mucosa — and that compounds restoring younger repair kinetics have potential healthspan implications. BPC-157 in particular has accumulated a striking volume of preclinical repair data across multiple tissue types.
As with the rest of this site, none of the compounds discussed is a licensed UK medicine. The research-context framing applies. BPC-157 in particular has had a controversial regulatory history in 2022–2023, with FDA bulk-list removal affecting US availability; UK MHRA framing remains that it is an unlicensed research compound.
The biology being targeted
Tissue repair across organ systems involves several common axes: angiogenesis (formation of new microvasculature), extracellular-matrix remodelling (collagen synthesis and lysyl-oxidase-mediated crosslinking), fibroblast proliferation and migration, and immune-cell recruitment with subsequent resolution. Peptide research has touched each of these axes.
GHK-Cu's central contribution is gene-regulatory and connective-tissue-organising: through copper trafficking to lysyl-oxidase, broad upregulation of extracellular-matrix gene expression, and anti-inflammatory effects through suppression of NF-κB-driven cytokine release in macrophages. The result is improved tensile strength of healed wounds and accelerated re-epithelialisation in rodent models.
BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic peptide derived from a sequence found in gastric juice. It is studied principally for effects on gastric mucosal repair, tendon and ligament healing, and vascular endothelial protection. Mechanistic work points to upregulation of VEGFR2 expression and modulation of growth-hormone receptor signalling.
Thymosin Beta-4 (TB-500) is a 43-amino-acid actin-sequestering peptide. It regulates G-actin/F-actin dynamics, which underpin cell migration during wound healing — particularly keratinocyte migration during re-epithelialisation and dermal fibroblast organisation. It is distinct from Thymosin Alpha-1 and operates through unrelated mechanisms.
Peptides researched in this protocol
Most-studied wound-healing peptide. Pickart 2008 (Biomaterials) demonstrated accelerated re-epithelialisation and improved tensile strength in rat full-thickness wound model. Gene-expression signature supports upregulation of DNA-repair, antioxidant-defence and matrix-component genes.
Stack combinations in the literature
BPC-157 + Thymosin Beta-4 is the canonical research-context combination for tendon and ligament repair. The mechanistic rationale is that BPC-157 provides angiogenic and growth-factor signalling while TB-500 supports cell-migration dynamics. No controlled clinical-trial data exists for this combination.
GHK-Cu topical or local application is sometimes combined with systemic BPC-157 in animal models of complex tissue injury. The mechanistic case is straightforward — GHK-Cu addresses local matrix biology while BPC-157 provides systemic vascular and growth-factor support — but combination-trial data is limited.
Evidence summary
GHK-Cu evidence is the strongest in this protocol vertical, with both substantial preclinical data and a published topical RCT in photoageing (Leyden et al. 2007). The mechanistic foundation (Pickart laboratory output from 1973 onwards) is the deepest of any compound covered here.
BPC-157 has a striking volume of preclinical literature — over 100 rodent studies across tendon, ligament, gastric, intestinal, cardiac and neural-tissue repair models — but no published human RCT. The translational gap is significant; the evidence base does not currently support BPC-157 as a clinically-validated repair intervention.
Thymosin Beta-4 has progressed further in human clinical development than BPC-157, with a phase II trial in pressure ulcers (RegeneRx programme) and several wound-healing studies. Outcomes have been mixed; no licensed indication has been achieved.
Safety profile & UK regulatory framing
GHK-Cu has the most-extensively-characterised safety profile, primarily through decades of cosmetic use. Parenteral GHK-Cu and research-grade preparations carry the standard 'research only' caveats.
BPC-157's safety profile in animal models is favourable across multiple species and dose ranges. Human safety data is essentially absent. The 2022 FDA bulk-substance-list removal in the US was not driven by adverse safety signals but by absence of evidence of historical compounding use — a regulatory rather than safety determination. UK MHRA framing is that BPC-157 is an unlicensed research compound.
Thymosin Beta-4 has a small human safety dataset from the RegeneRx clinical programme. Tolerability has been favourable in available trials; no organ-specific or mutagenic signal has emerged.
Under UK law, none of the compounds discussed is a licensed medicine for any recovery or tissue-repair indication.
Frequently asked questions
Is BPC-157 illegal in the UK?
BPC-157 is not a licensed UK medicine and is supplied only as a research peptide for laboratory and preclinical use. It is not on the UK's controlled-drugs schedules, but supply for human therapeutic use is not permitted under the Human Medicines Regulations 2012. The 2022 FDA bulk-list removal in the US does not directly affect UK regulatory status, which has always been research-only.
Does BPC-157 work for tendon injuries?
In preclinical rodent models, BPC-157 administration reliably accelerates tendon healing (improved tensile strength, faster collagen organisation) compared to vehicle controls. No published human RCT in tendon injury exists. The translational case is supported by mechanism and preclinical data; not by human trial evidence.
Is TB-500 the same as Thymosin Beta-4?
TB-500 is a synthetic 17-amino-acid peptide that corresponds to the active fragment of Thymosin Beta-4. The two terms are often used interchangeably in research-peptide literature, but technically TB-500 is the fragment and Thymosin Beta-4 is the full 43-amino-acid native peptide.
Why is BPC-157 controversial?
The preclinical literature is unusually broad (multiple tissue types, multiple species, large number of studies), but a substantial fraction comes from a single research group at the University of Zagreb. Independent replication outside the original group is present but more limited than the volume of the original work would suggest. Combined with the absence of human RCT data, this produces a strong-mechanism-weak-translation pattern that is genuinely controversial in the broader peptide-research community.